Roche contributes eight cancer medicines to IMPRESS-Norway.
Our school collaboration project has opened unexpected doors for Eivind.
Norwegian government to double the number of clinical studies.
Dehns acquires Norwegian Intellectual Property consultancy Leogriff.
Ultimovacs has announced a new clinical study targeted at patients with ovarian cancer.
CONNECT is a completely new public-private collaboration in cancer precision medicine.